Impact of a Novel Dehydroepiandrosterone Derivative on the Metabolism of RWPE-1 and LNCaP Cell Lines
June 2026
in “
Oriental Journal Of Chemistry
”
TLDR Steroid 12 shows promise as a targeted treatment for prostate cancer by selectively reducing cell growth and increasing cell death.
The study examines the impact of a novel dehydroepiandrosterone derivative, steroid 12, on the metabolism of normal (RWPE-1) and tumorigenic (LNCaP) prostate cells. Steroid 12 significantly reduces cell viability and increases apoptosis in testosterone-stimulated cells, but not in those stimulated with dihydrotestosterone, unlike finasteride and dutasteride, which affect both. This suggests steroid 12's potential as a targeted therapeutic agent in prostate cancer treatment. It is more potent than finasteride in reducing RWPE-1 cell growth, while dutasteride remains the most effective inhibitor. The study highlights steroid 12's selective mechanism and its promise as a more effective treatment compared to existing inhibitors.
